5 completed, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 11 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Larynx Cancer: new trials by email Literature Review of Larynx Cancer trials Research Report on Larynx Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE) Capecitabine, Standard of Care (SOC) - Head Neck Cancer, Mouth Cancer | Phase 2 | Not yet recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 75 | 2026-01-01 | 2025-11-28 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer Surgery, Radiation, Toripalimab - Larynx Cancer, Hypopharyngeal Cancer | Phase 2 | Recruiting | Fudan University | 82 | 2023-08-22 | 2023-09-15 |
| Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Vocal-cord Radiotherapy, Complete Larynx Radiotherapy - Cancer Neck, Larynx Cancer | Phase 2 | Active not recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 155 | 2018-10-11 | 2025-03-21 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Durvalumab, Carboplatin, Nab-paclitaxel - Carcinoma, Squamous Cell, Oral Cancer | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 39 | 2017-12-19 | 2026-02-23 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Pembrolizumab, Cetuximab - HNSCC, Lip SCC | Phase 2 | Completed | University of California, San Diego | 78 | 2017-03-28 | 2026-10-01 |
| Adaptive Radiotherapy for Head and Neck Cancer Adaptive Radiotherapy - Head and Neck Cancer, Paranasal Sinus Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 64 | 2017-03-15 | 2021-10-26 |
| Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer laryngoscopy, Taxotere (Docetaxel), Cisplatin, 5FU - Larynx Cancer | Phase 2 | Unknown | Rabin Medical Center | 100 | 2010-04-01 | 2010-03-05 |
| Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation cetuximab, Cisplatin, Radiotherapy 70 Gy, 35 fractions - Larynx Cancer, Hypopharynx Cancer | Phase 2 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 156 | 2005-10-01 | 2011-06-27 |
| Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID), Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID), CDDP, 5 Fu - Oropharynx Cancer, Oral Cancer | Phase 2 / Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 120 | 1996-07-01 | 2026-08-19 |
Laryngeal Neoplasms (11) · Mouth Neoplasms (7) · Hypopharyngeal Neoplasms (6) · Head and Neck Neoplasms (5) · Oropharyngeal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (4) · Lip Neoplasms (2) · Nasopharyngeal Neoplasms (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1)
Laryngeal Diseases (11) · Neoplasms (11) · Neoplasms by Site (11) · Otorhinolaryngologic Diseases (11) · Otorhinolaryngologic Neoplasms (11) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (11) · Stomatognathic Diseases (9) · Pharyngeal Diseases (8) · Pharyngeal Neoplasms (8) · Mouth Diseases (7) · Head and Neck Neoplasms (6) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5)
Cetuximab (3) · Cisplatin (3) · Fluorouracil (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Carboplatin (1) · Docetaxel (1) · Laryngoscopy (1) · Radiation (1) · Radiotherapy, Intensity-Modulated (1) · Standard of Care (1) · Surgical Procedures, Operative (1) · durvalumab (1) · pembrolizumab (1)
Memorial Sloan Kettering Cancer Center (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Fudan University (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Klus Pharma Inc. (1) · Rabin Medical Center (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, San Diego (1)
United States (6) · France (2) · Canada (1) · China (1) · Israel (1)
Aron Popovtzer, MD (1) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · David Palma (1) · Houda Bahig (1) · Jacques Tortochaux (1) · Jared Weiss, MD (1) · Jean Bourhis (1) · Jean-Louis Lefebvre (1) · Jordi Rodon Ahnert, MD, PhD (1) · Marco Mascarella, MD, MSc, PhD (1) · Michel Lapeyre (1) · Winston Wong, MD (1)